AmideBio
About:
AmideBio develops and commercializes peptide research reagents and clinical products for clinical and therapeutic marketplaces.
Website: http://AmideBio.com
Top Investors: National Institute of Diabetes and Digestive and Kidney Diseases
Description:
AmideBio, LLC, a biotechnology company, focuses on the development, production, and commercialization of peptide research reagents and clinical products for research and development, clinical, and therapeutic marketplaces.
Total Funding Amount:
$7.21M
Estimated Revenue Range:
$10M to $50M
Headquarters Location:
Louisville, Colorado, United States
Founded Date:
2009-01-01
Contact Email:
info(AT)amidebio.com
Founders:
Michael H. B Stowell, Mikhail Misha Plam
Number of Employees:
1-10
Last Funding Date:
2024-09-11
IPO Status:
Private
Industries:
© 2025 bioDAO.ai